FDA should focus on real health priorities

Years ago, when "GAO" stood for "General Accounting Office," that arm of Congress focused its reviews on how well government agencies were spending taxpayers' resources. A new GAO report suggests FDA should expend more resources on substances earlier determined to be safe, some, like salt, of proven safety since before the founding of FDA or even the founding of the United States. GRAS has been a prime achievement in wise use of taxpayer monies in that it has allowed the agency to accept substances in foods which had been used safely for centuries, enabling FDA to focus on substances with unproven food safety.

Salt was the original, archetypical GRAS substance.

No one should doubt the safety of salt. The petitioners would have FDA regulate the amount of salt allowed in each serving of food. There is no evidence that this would produce either of the benefits the petitioners assert. No studies have been done that show that those consuming diets incorporating low-salt foods result in lower overall salt consumption. Evidence shows that salt appetite responds to an individual's physiologic need. Neither is there any controlled trial of whether diets lower in salt or sodium produce better health outcomes. Nearly every one of the few studies that have been done show either no benefit or even increased risk. In fact, the two controlled trials reported to date both show worse outcomes for those on lower sodium intakes.

GAO should go back to serving the taxpayers in assessing whether government agencies are using good judgment in prioritizing limited resources on real problems. The GRAS status of salt is a PR sideshow unworthy diverting FDA from its vital mission of ensuring the safety of America's food supplies. GAO would be well served to ask why NHLBI continues to fund PR-oriented studies offering computer models of blood pressure impacts of low-salt diets when that question is well-studied and by NHLBI continues to frustrate efforts, including those of the 2005 Dietary Guidelines Advisory Committee, to have the federal government conduct a meaningful controlled health outcomes study of whether lower sodium diets would improve public health. Until that study is done, FDA is right to prioritize its resources to questions where evidence suggests the public will get better bang for its buck.